期刊
JOURNAL OF ALZHEIMERS DISEASE
卷 44, 期 1, 页码 283-295出版社
IOS PRESS
DOI: 10.3233/JAD-140798
关键词
Aerosol; Alzheimer's disease; amyloid imaging; amyloid plaques; atomization; inhalation exposure; clinical translation; curcumin
资金
- National Institutes of Health [R01CA16700, T32 EB014841]
- VICC Cancer Center Support grant
- Grants-in-Aid for Scientific Research [26290022, 26670554] Funding Source: KAKEN
- NATIONAL CANCER INSTITUTE [R01CA160700] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [T32EB014841] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007347] Funding Source: NIH RePORTER
Curcumin is a promising compound that can be used as a theranostic agent to aid research in Alzheimer's disease. Beyond its ability to bind to amyloid plaques, the compound can also cross the blood-brain barrier. Presently, curcumin can be applied only to animal models, as the formulation needed for iv injection renders it unfit for human use. Here, we describe a novel technique to aerosolize a curcumin derivative, FMeC1, and facilitate its safe delivery to the brain. Aside from the translational applicability of this approach, a study in the 5XFAD mouse model suggested that inhalation exposure to an aerosolized FMeC1 modestly improved the distribution of the compound in the brain. Additionally, immunohistochemistry data confirms that following aerosol delivery, FMeC1 binds amyloid plaques expressed in the hippocampal areas and cortex.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据